Humanin Dosage Chart: 0.5-2mg HNG Daily Protocol

Humanin is a 24-amino acid mitochondrial-derived peptide originally discovered in 2001 as a factor protecting neurons from Alzheimer's disease-related cell death. The potent analog HNG (S14G-humanin) is most commonly used. This is not medical advice.

Research-context information only. Humanin is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Quick Reference: Community Protocol

Humanin has no standardized clinical dosing protocol — this is a community protocol based on animal research extrapolation and empirical reports. Native humanin is rarely used due to HNG's 1,000x greater potency.

Cycling Details

Community protocols typically begin at 0.5 mg HNG daily during Week 1, advancing to 1–2 mg if well-tolerated. Most community users settle at 1 mg daily as their standard protocol.

The 8-12 week on / 4-8 week off cycling approach is conservative given the complete absence of human clinical trial data for exogenous supplementation. Natural humanin levels are constant (declining with age), so the cycling rationale is precautionary rather than evidence-based.

Routes of Administration

Subcutaneous (community standard): Abdomen, love handles, or thighs. Volume is typically 0.1-0.3 mL with insulin syringe. Once daily, morning.

Intravenous / Intracerebroventricular: IV and ICV routes appear only in animal study protocols; subcutaneous administration is the route documented in community sources.

Reconstitution Quick Reference

The dilution ratios below reflect concentrations documented in community reconstitution sources and are presented as reference math, not a dosing schedule.

Math: 5,000 mcg / 2 mL = 2,500 mcg/mL. 1,000 mcg / 2,500 = 0.4 mL = 40 units. Swirl gently, refrigerate, use within 28 days.

For step-by-step reconstitution instructions, see the BPC-157 reconstitution guide — same technique applies to all lyophilized peptides.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

Humanin research is extensive in animal and cell models but completely lacks human clinical trials for exogenous supplementation.

Humanin was discovered by Hashimoto et al. through a functional screen of cDNA from an Alzheimer's disease patient's brain, identified as a factor that protected neurons from amyloid-beta toxicity (Hashimoto et al., 2001). A landmark study demonstrated that humanin overexpression extends lifespan in C. elegans through daf-16/FOXO-dependent mechanisms (Muzumdar et al., 2020).

Humanin directly prevents mitochondrial membrane permeabilization by inhibiting Bax and Bid oligomerization — a key step in the intrinsic apoptosis pathway (Bhatt et al., 2017). The analog HNG also improves insulin sensitivity and enhances glucose-stimulated insulin secretion (Kuliawat et al., 2013).

No human clinical trials exist for exogenous humanin/HNG supplementation. Dosing is entirely extrapolated from animal pharmacokinetic data, in vitro bioactive concentrations, the peptide's natural age-related decline, and community experience.

Stacking Protocols

Community protocols describe introducing each peptide individually before combining. Community sources describe rotating injection sites when running multiple peptides simultaneously. Community resources commonly note that anti-apoptotic peptides raise theoretical concerns in the presence of active malignancy; current cancer screening is frequently listed as a precondition in community protocols.

Side Effects & Safety

• Generally well-tolerated at 0.5-2 mg HNG daily in community reports
• Injection site reactions — standard mild redness, occasional irritation
• Mild fatigue — occasional, usually transient
• Anti-apoptotic concern — humanin's potent anti-apoptotic activity raises theoretical questions about cancer risk; community protocols typically exclude active malignancy given humanin's anti-apoptotic mechanism
• Metabolic effects — community reports describe enhanced insulin sensitivity; users with diabetes in community sources note monitoring blood glucose
• No serious adverse events reported in community forums or animal studies
• Pregnancy/lactation — no safety data exists for pregnancy or lactation; community protocols exclude these populations

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once humanin is reconstituted, the conversion from a target dose to syringe units depends on the chosen dilution.

The two reconstitution ratios most often described in community protocols are below.

Reconstitution A: 5 mg vial + 2 mL BAC water (2.5 mg/mL) — the standard dilution from the Quick Reference above.

Reconstitution B: 5 mg vial + 1 mL BAC water (5 mg/mL) — less BAC water for a lower total volume, so smaller draws and less fridge space.

These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.